Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III
Identifieur interne : 00A953 ( Main/Exploration ); précédent : 00A952; suivant : 00A954Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III
Auteurs : Ronnie Willenheimer [Suède] ; Erland Erdmann [Allemagne] ; Ferenc Follath [Suisse] ; Henry Krum [Australie] ; Piotr Ponikowski [Pologne] ; Bernard Silke [Irlande (pays)] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Louis Van De Ven [Allemagne] ; Patricia Verkenne [Allemagne] ; Philippe Lechat [France]Source :
- European Journal of Heart Failure [ 1388-9842 ] ; 2004-06.
Descripteurs français
- Wicri :
- topic : Hospitalisation.
English descriptors
- KwdEn :
- American college, Better chance, Bisoprolol, Blocker, Cardiac insufficiency bisoprolol study, Cardiology, Cardiovascular causes, Central telephone randomisation procedure, Chronic heart failure, Cibis, Clinical practice, Coll cardiol, Combination therapy, Confidence interval, Congestive heart failure, Decrease hospitalisation, Dos, Drug treatment, Early introduction, Early stages, Elderly patients, Enalapril, Endpoint, Endpoint evaluation, Enzyme inhibitors, European journal, European society, Event rate, Fewer patients, First treatment, Guideline, Heart failure, Heart rate, Hospitalisation, Independent endpoint committee, Individual judgement, Inhibitor, Initial monotherapy, Lancet, Maintenance dose, Merck kgaa, Metoprolol cryxl, Monotherapy, Monotherapy phase, Morbidity, Mortalityymorbidity trials, Nyha class, Open design, Operative conduct, Optimal order, Optimum doses, Plasma norepinephrine, Premature treatment withdrawals, Primary endpoint, Primary objective, Randomisation, Randomised, Randomised patients, Randomized trials, Renal insufficiency, Respective agents, Sample size, Second agent, Second drug, Second step, Separate adjustment, Serum creatinine, Show superiority, Side effect, Side effects, Standard therapy, Statistical analysis, Study group, Study medication, Such case, Sudden death, Symptomatic heart failure, Target dose, Target doses, Time point, Titration steps, Ventricular dysfunction, Ventricular ejection fraction, Willenheimer.
- Teeft :
- American college, Better chance, Bisoprolol, Blocker, Cardiac insufficiency bisoprolol study, Cardiology, Cardiovascular causes, Central telephone randomisation procedure, Chronic heart failure, Cibis, Clinical practice, Coll cardiol, Combination therapy, Confidence interval, Congestive heart failure, Decrease hospitalisation, Dos, Drug treatment, Early introduction, Early stages, Elderly patients, Enalapril, Endpoint, Endpoint evaluation, Enzyme inhibitors, European journal, European society, Event rate, Fewer patients, First treatment, Guideline, Heart failure, Heart rate, Hospitalisation, Independent endpoint committee, Individual judgement, Inhibitor, Initial monotherapy, Lancet, Maintenance dose, Merck kgaa, Metoprolol cryxl, Monotherapy, Monotherapy phase, Morbidity, Mortalityymorbidity trials, Nyha class, Open design, Operative conduct, Optimal order, Optimum doses, Plasma norepinephrine, Premature treatment withdrawals, Primary endpoint, Primary objective, Randomisation, Randomised, Randomised patients, Randomized trials, Renal insufficiency, Respective agents, Sample size, Second agent, Second drug, Second step, Separate adjustment, Serum creatinine, Show superiority, Side effect, Side effects, Standard therapy, Statistical analysis, Study group, Study medication, Such case, Sudden death, Symptomatic heart failure, Target dose, Target doses, Time point, Titration steps, Ventricular dysfunction, Ventricular ejection fraction, Willenheimer.
Abstract
Angiotensin‐converting‐enzyme (ACE) inhibitors and β‐blockers are standard therapy for chronic heart failure (CHF). β‐blockers are recommended to be initiated after ACE‐inhibitors, but this order is not evidence based. The initiation order may be important since many, especially elderly CHF patients cannot tolerate target doses of both. Data suggest that β‐blockers may be more important to CHF patients than ACE‐inhibitors, especially in early stages of CHF.
Url:
DOI: 10.1016/j.ejheart.2003.12.016
Affiliations:
- Allemagne, Australie, France, Irlande (pays), Pays-Bas, Pologne, Suisse, Suède
- District de Darmstadt, Hesse (Land), Victoria (État), Île-de-France
- Darmstadt, Melbourne, Paris
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002A10
- to stream Istex, to step Curation: 002A10
- to stream Istex, to step Checkpoint: 001A31
- to stream Main, to step Merge: 00B610
- to stream Main, to step Curation: 00A953
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III</title><author><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name></author><author><name sortKey="Erdmann, Erland" sort="Erdmann, Erland" uniqKey="Erdmann E" first="Erland" last="Erdmann">Erland Erdmann</name></author><author><name sortKey="Follath, Ferenc" sort="Follath, Ferenc" uniqKey="Follath F" first="Ferenc" last="Follath">Ferenc Follath</name></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></author><author><name sortKey="Ponikowski, Piotr" sort="Ponikowski, Piotr" uniqKey="Ponikowski P" first="Piotr" last="Ponikowski">Piotr Ponikowski</name></author><author><name sortKey="Silke, Bernard" sort="Silke, Bernard" uniqKey="Silke B" first="Bernard" last="Silke">Bernard Silke</name></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></author><author><name sortKey="Van De Ven, Louis" sort="Van De Ven, Louis" uniqKey="Van De Ven L" first="Louis" last="Van De Ven">Louis Van De Ven</name></author><author><name sortKey="Verkenne, Patricia" sort="Verkenne, Patricia" uniqKey="Verkenne P" first="Patricia" last="Verkenne">Patricia Verkenne</name></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E0E02A64E7E85C615A4317FBFB8C04CC1FE50C1D</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1016/j.ejheart.2003.12.016</idno><idno type="url">https://api.istex.fr/document/E0E02A64E7E85C615A4317FBFB8C04CC1FE50C1D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A10</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002A10</idno><idno type="wicri:Area/Istex/Curation">002A10</idno><idno type="wicri:Area/Istex/Checkpoint">001A31</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A31</idno><idno type="wicri:doubleKey">1388-9842:2004:Willenheimer R:comparison:of:treatment</idno><idno type="wicri:Area/Main/Merge">00B610</idno><idno type="wicri:Area/Main/Curation">00A953</idno><idno type="wicri:Area/Main/Exploration">00A953</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III</title><author><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Cardiology, University Hospital, S‐205 02, Malmö</wicri:regionArea><wicri:noRegion>Malmö</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Suède</country></affiliation></author><author><name sortKey="Erdmann, Erland" sort="Erdmann, Erland" uniqKey="Erdmann E" first="Erland" last="Erdmann">Erland Erdmann</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medizinische Klinik III, University of Cologne</wicri:regionArea><wicri:noRegion>University of Cologne</wicri:noRegion><wicri:noRegion>University of Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Follath, Ferenc" sort="Follath, Ferenc" uniqKey="Follath F" first="Ferenc" last="Follath">Ferenc Follath</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Medicine A, University Hospital Zürich</wicri:regionArea><wicri:noRegion>University Hospital Zürich</wicri:noRegion></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Departments of Epidemiology and Preventive Medicine and Medicine, Monash University, Alfred Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Ponikowski, Piotr" sort="Ponikowski, Piotr" uniqKey="Ponikowski P" first="Piotr" last="Ponikowski">Piotr Ponikowski</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Cardiology Department, Clinical Military Hospital, Wroclaw</wicri:regionArea><wicri:noRegion>Wroclaw</wicri:noRegion></affiliation></author><author><name sortKey="Silke, Bernard" sort="Silke, Bernard" uniqKey="Silke B" first="Bernard" last="Silke">Bernard Silke</name><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Pharmacology and Therapeutics, Trinity Centre, St James’ Hospital, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Thoraxcenter, Department of Cardiology, University Hospital Groningen</wicri:regionArea><wicri:noRegion>University Hospital Groningen</wicri:noRegion></affiliation></author><author><name sortKey="Van De Ven, Louis" sort="Van De Ven, Louis" uniqKey="Van De Ven L" first="Louis" last="Van De Ven">Louis Van De Ven</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KgaA, Darmstadt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Darmstadt</settlement></placeName></affiliation></author><author><name sortKey="Verkenne, Patricia" sort="Verkenne, Patricia" uniqKey="Verkenne P" first="Patricia" last="Verkenne">Patricia Verkenne</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KgaA, Darmstadt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Darmstadt</settlement></placeName></affiliation></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie, Hopital Pitié‐Salpetriere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">European Journal of Heart Failure</title><title level="j" type="alt">EUROPEAN JOURNAL OF HEART FAILURE</title><idno type="ISSN">1388-9842</idno><idno type="eISSN">1879-0844</idno><imprint><biblScope unit="vol">6</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="493">493</biblScope><biblScope unit="page" to="500">500</biblScope><biblScope unit="page-count">8</biblScope><date type="published" when="2004-06">2004-06</date></imprint><idno type="ISSN">1388-9842</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1388-9842</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>American college</term><term>Better chance</term><term>Bisoprolol</term><term>Blocker</term><term>Cardiac insufficiency bisoprolol study</term><term>Cardiology</term><term>Cardiovascular causes</term><term>Central telephone randomisation procedure</term><term>Chronic heart failure</term><term>Cibis</term><term>Clinical practice</term><term>Coll cardiol</term><term>Combination therapy</term><term>Confidence interval</term><term>Congestive heart failure</term><term>Decrease hospitalisation</term><term>Dos</term><term>Drug treatment</term><term>Early introduction</term><term>Early stages</term><term>Elderly patients</term><term>Enalapril</term><term>Endpoint</term><term>Endpoint evaluation</term><term>Enzyme inhibitors</term><term>European journal</term><term>European society</term><term>Event rate</term><term>Fewer patients</term><term>First treatment</term><term>Guideline</term><term>Heart failure</term><term>Heart rate</term><term>Hospitalisation</term><term>Independent endpoint committee</term><term>Individual judgement</term><term>Inhibitor</term><term>Initial monotherapy</term><term>Lancet</term><term>Maintenance dose</term><term>Merck kgaa</term><term>Metoprolol cryxl</term><term>Monotherapy</term><term>Monotherapy phase</term><term>Morbidity</term><term>Mortalityymorbidity trials</term><term>Nyha class</term><term>Open design</term><term>Operative conduct</term><term>Optimal order</term><term>Optimum doses</term><term>Plasma norepinephrine</term><term>Premature treatment withdrawals</term><term>Primary endpoint</term><term>Primary objective</term><term>Randomisation</term><term>Randomised</term><term>Randomised patients</term><term>Randomized trials</term><term>Renal insufficiency</term><term>Respective agents</term><term>Sample size</term><term>Second agent</term><term>Second drug</term><term>Second step</term><term>Separate adjustment</term><term>Serum creatinine</term><term>Show superiority</term><term>Side effect</term><term>Side effects</term><term>Standard therapy</term><term>Statistical analysis</term><term>Study group</term><term>Study medication</term><term>Such case</term><term>Sudden death</term><term>Symptomatic heart failure</term><term>Target dose</term><term>Target doses</term><term>Time point</term><term>Titration steps</term><term>Ventricular dysfunction</term><term>Ventricular ejection fraction</term><term>Willenheimer</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>American college</term><term>Better chance</term><term>Bisoprolol</term><term>Blocker</term><term>Cardiac insufficiency bisoprolol study</term><term>Cardiology</term><term>Cardiovascular causes</term><term>Central telephone randomisation procedure</term><term>Chronic heart failure</term><term>Cibis</term><term>Clinical practice</term><term>Coll cardiol</term><term>Combination therapy</term><term>Confidence interval</term><term>Congestive heart failure</term><term>Decrease hospitalisation</term><term>Dos</term><term>Drug treatment</term><term>Early introduction</term><term>Early stages</term><term>Elderly patients</term><term>Enalapril</term><term>Endpoint</term><term>Endpoint evaluation</term><term>Enzyme inhibitors</term><term>European journal</term><term>European society</term><term>Event rate</term><term>Fewer patients</term><term>First treatment</term><term>Guideline</term><term>Heart failure</term><term>Heart rate</term><term>Hospitalisation</term><term>Independent endpoint committee</term><term>Individual judgement</term><term>Inhibitor</term><term>Initial monotherapy</term><term>Lancet</term><term>Maintenance dose</term><term>Merck kgaa</term><term>Metoprolol cryxl</term><term>Monotherapy</term><term>Monotherapy phase</term><term>Morbidity</term><term>Mortalityymorbidity trials</term><term>Nyha class</term><term>Open design</term><term>Operative conduct</term><term>Optimal order</term><term>Optimum doses</term><term>Plasma norepinephrine</term><term>Premature treatment withdrawals</term><term>Primary endpoint</term><term>Primary objective</term><term>Randomisation</term><term>Randomised</term><term>Randomised patients</term><term>Randomized trials</term><term>Renal insufficiency</term><term>Respective agents</term><term>Sample size</term><term>Second agent</term><term>Second drug</term><term>Second step</term><term>Separate adjustment</term><term>Serum creatinine</term><term>Show superiority</term><term>Side effect</term><term>Side effects</term><term>Standard therapy</term><term>Statistical analysis</term><term>Study group</term><term>Study medication</term><term>Such case</term><term>Sudden death</term><term>Symptomatic heart failure</term><term>Target dose</term><term>Target doses</term><term>Time point</term><term>Titration steps</term><term>Ventricular dysfunction</term><term>Ventricular ejection fraction</term><term>Willenheimer</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Hospitalisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Angiotensin‐converting‐enzyme (ACE) inhibitors and β‐blockers are standard therapy for chronic heart failure (CHF). β‐blockers are recommended to be initiated after ACE‐inhibitors, but this order is not evidence based. The initiation order may be important since many, especially elderly CHF patients cannot tolerate target doses of both. Data suggest that β‐blockers may be more important to CHF patients than ACE‐inhibitors, especially in early stages of CHF.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Irlande (pays)</li><li>Pays-Bas</li><li>Pologne</li><li>Suisse</li><li>Suède</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Darmstadt</li><li>Melbourne</li><li>Paris</li></settlement></list><tree><country name="Suède"><noRegion><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name></noRegion><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name></country><country name="Allemagne"><noRegion><name sortKey="Erdmann, Erland" sort="Erdmann, Erland" uniqKey="Erdmann E" first="Erland" last="Erdmann">Erland Erdmann</name></noRegion><name sortKey="Van De Ven, Louis" sort="Van De Ven, Louis" uniqKey="Van De Ven L" first="Louis" last="Van De Ven">Louis Van De Ven</name><name sortKey="Verkenne, Patricia" sort="Verkenne, Patricia" uniqKey="Verkenne P" first="Patricia" last="Verkenne">Patricia Verkenne</name></country><country name="Suisse"><noRegion><name sortKey="Follath, Ferenc" sort="Follath, Ferenc" uniqKey="Follath F" first="Ferenc" last="Follath">Ferenc Follath</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></region></country><country name="Pologne"><noRegion><name sortKey="Ponikowski, Piotr" sort="Ponikowski, Piotr" uniqKey="Ponikowski P" first="Piotr" last="Ponikowski">Piotr Ponikowski</name></noRegion></country><country name="Irlande (pays)"><noRegion><name sortKey="Silke, Bernard" sort="Silke, Bernard" uniqKey="Silke B" first="Bernard" last="Silke">Bernard Silke</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A953 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A953 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E0E02A64E7E85C615A4317FBFB8C04CC1FE50C1D
|texte= Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III
}}
| This area was generated with Dilib version V0.6.33. |  |